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Abstract
Background: Recent studies have indicated the presence of multipotent mesenchymal stromal cells (MSCs) in
human lung diseases. Excess airway smooth muscle, myofibroblasts and activated fibroblasts have each been
noted in asthma, suggesting that mesenchymal progenitor cells play a role in asthma pathogenesis. We therefore
sought to determine whether MSCs are present in the lungs of ovalbumin (OVA)-sensitized and challenged mice, a
model of allergic airways disease.
Methods: Balb/c mice were sensitized and challenged with PBS or OVA over a 25 day period. Flow cytometry as
well as colony forming and differentiation potential were used to analyze the emergence of MSCs along with gene
expression studies using immunochemical analyses, quantitative polymerase chain reaction (qPCR), and gene
expression beadchips.
Results: A CD45-negative subset of cells expressed Stro-1, Sca-1, CD73 and CD105. Selection for these markers and
negative selection against CD45 yielded a population of cells capable of adipogenic, osteogenic and chondrogenic
differentiation. Lungs from OVA-treated mice demonstrated a greater average colony forming unit-fibroblast
(CFU-F) than control mice. Sorted cells differed from unsorted lung adherent cells, exhibiting a pattern of gene
expression nearly identical to bone marrow-derived sorted cells. Finally, cells isolated from the bronchoalveolar
lavage of a human asthma patient showed identical patterns of cell surface markers and differentiation potential.
Conclusions: In summary, allergen sensitization and challenge is accompanied by an increase of MSCs resident in
the lungs that may regulate inflammatory and fibrotic responses.
Introduction
Adult bone marrow contains a minority population of
mesenchymal stem cells that are thought to contribute
to the regeneration of connective tissues such as bone,
cartilage, muscle, ligaments, tendons, fat and stroma
[1]. These cells demonstrate cell surface markers con-
sistent with a mesenchymal origin (e.g., Stro-1, Sca-1,
CD73, CD90, CD105) but fail to express markers asso-
ciated with a hematopoietic (CD34, CD45) or endothe-
lial cell (CD31) origin. Subsequently, multipotent
mesenchymal stem cells were isolated from peripheral
sites, including peripheral blood [2], adipose tissue [3],
articular synovium [4] and trabecular bone [5]. More
recently, it has been suggested that most organs appar-
ently carry their own population of pluripotent
mesenchymal stem cells in a perivascular compartment
that participate in tissue repair [6]. The perivascular
niche has been demonstrated to be the source of
mesenchymal stem cells in adipose tissue [7], skeletal
muscle [8] and other organs [9].
With regard to the lung, mesenchymal stem cells
have been isolated from the bronchial tissue of
patients undergoing lobectomy for primary lung
tumors [10]. Our laboratory has isolated mesenchymal
stem cells from the tracheal aspirates of premature
infants undergoing mechanical ventilation for
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respiratory distress [11]. Mesenchymal stem cells of
donor sex identity have been found in lung allografts
years after transplantation, suggesting that these
stromal cells may originate from the lung tissue itself,
perhaps from the perivascular compartment [12].
Finally, we [13] and others [14,15] have shown that, in
addition to the above cell types, mesenchymal stem
cells may undergo differentiation to myofibroblasts.
Recent work suggests that there is a hierarchy of mul-
tipotent mesenchymal stromal cells ranging from true
self-renewing stem cells with multilineage differentiation
capacity to those with more restricted differentiation
potential, until a state of complete restriction to the
fibroblast is reached [16]. Since the clonogenicity or
self-renewal of most mesenchymal stem cell isolates has
not been thoroughly tested, we now refer to cells with
the surface markers and differentiation potential of
mesenchymal stem cells as mesenchymal stromal cells
(MSCs), which have a more restricted differentiation
potential.
There is abundant evidence in the literature suggest-
ing that mesenchymal progenitor cells are involved in
asthma pathogenesis. Excess airway smooth muscle,
caused in part by an increase in the number of smooth
muscle cells, has been well-described in asthma
[17,18]. Patients with severe asthma also demonstrate
an accumulation of myofibroblasts in the airway sube-
pithelium [19-22]. These alterations may extend
beyond the central airways to the distal airways and
lung parenchyma [23]. Finally, in contrast to control
subjects, “activated” fibroblasts have been identified in
the bronchoalveolar lavage (BAL) fluid of patients with
asthma [24]. We therefore hypothesized that multipo-
tent MSCs, which may serve as progenitor cells of
smooth muscle cells and myofibroblasts, are increased
in the lungs of ovalbumin-sensitized and -challenged
mice, an animal model of allergic airways disease. Pre-
vious studies have demonstrated hyperplasia of myofi-
broblasts in both the large and small airways of these
mice, including the terminal bronchioles, alveolar
ducts and alveolar walls [25].
Materials and methods
OVA-sensitization and challenge
Mice (BALB/cByJ, Jackson Labs, Bar Harbor, ME) were
sensitized to sterile LPS-free OVA (Pierce, Rockford, IL)
or PBS control by intraperitoneal injection and serially
challenged over a month with intranasal instillations of
OVA or PBS (Figure 1), as previously described [26,27].
This study was approved by the Institutional Animal
Care and Use Committee.
Flow cytometry of whole lung digests and adherent cells
Lungs from PBS- and OVA-treated mice were perfused
with 5 mM EDTA, minced into 1-2 mm blocks and
digested for 1 hr in 5 mg/ml collagenase. Cells were
obtained by filtration through a 70 μm mesh. Red blood
cells were lysed with an ammonium chloride buffer.
Cells were washed in 10% serum-containing DMEM
with 4 mM glucose, 1 mM sodium pyruvate, and 2 mM
L-glutamine and plated at 106 cells/100 mm dish. After
5 days, adherent cells were removed from the plates by
trypsin, washed with Ca2+, Mg2+-containing PBS and
blocked with 1% BSA in PBS for 20 min at 4°C. Within
three hours after immunostaining (below), cells were
sorted using a BD Biosciences FACSDiVa High-Speed
Cell Sorter (San Diego, CA) with 350 nm, 488 nm, and
633 nm lasers. Cells were stained with 2.5 μg/mL of
FITC- or AlexaFluor (AF)-conjugated antibodies. Typi-
cally, anti-Stro-1 was conjugated to AF 350, anti-CD34
was conjugated to FITC, anti-CD105 was coupled to
AF555, anti-CD73 was coupled to AF633 and anti-CD45
was conjugated to AF750. Cells were negatively selected
for CD34 and CD45 and positively selected for Stro-1,
CD73 and CD105 binding (see text). Cells were col-
lected in 1 mL DMEM supplemented with 10% FBS and
cultured for 2 weeks to allow colony formation before
expansion for study.
Determination of colony forming unit-fibroblast (CFU-F)
Lungs from PBS- and OVA-treated mice were perfused
with 5 mM EDTA, minced into 1-2 mm blocks and
digested for 1 hr in 5 mg/ml collagenase. Cells were
Figure 1 Schema for OVA sensitization and challenge of mice, isolation of a total lung fibroblast fraction, and sorting of a
mesenchymal stromal cell fraction. Mice were sensitized twice by intraperitoneal (IP) injections at day 0 and day 11 of OVA followed by
intranasal (IN) challenges at days 11, 18, 21, 22, and 23. Lungs were isolated, digested with collagenase, and adherent cells plated with daily
media changes to remove nonadherent cells. At the end of 5 days, adherent cells were lifted, sorted and, in two additional weeks, processed for
colony formation.
Bentley et al. Respiratory Research 2010, 11:127
http://respiratory-research.com/content/11/1/127
Page 2 of 15
obtained by filtration through a 70 μm mesh. Trypan
blue-excluding cells from each animal were serially
diluted and plated in DMEM with 10% FBS at 100 cells/
well in 2 mL of medium into a 30 mm well of a 6 well
dish (in triplicate). Cells were allowed to grow in 10%
FBS/DMEM for 14 days. After 14 days, plates were
stained with 0.5% toluidine blue for 5 min, washed three
times with PBS, and independent colonies of primary
mouse lung fibroblasts were counted, as described pre-
viously [28]. A similar procedure was followed to deter-
mine the CFU-F of sorted Stro-, CD73, CD105-positive
mouse lung MSCs.
Analysis of cultured sorted cells from the lungs of OVA-
sensitized and challenged mice
Cells (passage 3-5 post-sort) were dissociated from plas-
tic using cell dissociation buffer (PBS supplemented
with 5 mM EDTA) and analyzed for the surface markers
described above, as well as CD90.2 (rat anti-mouse Thy
1.2, clone 30-H12, BD Pharmingen) and Sca-1 (rat anti-
mouse Ly 6-A/E, clone e13-161.7, BD Pharmingen).
Cells were typically stained with 2 μg/mL FITC- or
AF488-conjugated antibodies or isotypic control immu-
noglobulins and 50 μg/mL propidium iodide.
Fluorescence microscopy
The pulmonary artery was perfused with EDTA.
Mouse lung vasculature was perfused with 5 mM
EDTA in PBS injected through the pulmonary artery
until the lung blanched. Lungs were inflated to 30 cm
H2O pressure with 4% paraformaldehyde (Sigma-
Aldrich, St. Louis, MO) and placed in formalin over-
night. Paraffin-embedded lungs were sectioned with
5 μm-thick sections. AlexaFluor (AF) dye antibody
conjugates were prepared using N-hydroxy succinimide
esterified dye conjugation reactions with 20 μg anti-
body and 100 μg activated dye in 10 mM sodium
bicarbonate buffer (pH 8.5) for 1 hour. The reaction
was quenched by making it 500 mM Tris HCl pH 7.2
for 1 hour, and the conjugated antibody was purified
by separating it from quenched dye over a G-50 spin
column (GE Healthcare, Piscataway, NJ). Slides were
probed with 2 μg/mL AF or fluorescein isothiocyanate
(FITC)-conjugated anti-Stro-1 (clone STRO-1, R&D
Systems, Minneapolis, MN), anti-CD34 clone
MEC14.7, anti-CD45 clone 30-F11, anti-CD73 clone
TY/11.8, anti CD105 clone MJ7/18 (each from BioLe-
gend, San Diego, CA) and Cy3- or FITC-conjugated
mouse anti-a-smooth muscle actin (clone 1A4, Sigma-
Aldrich). Nuclei were visualized with 10 μg/mL
Hoechst 33258 (Sigma-Aldrich). Cells were imaged
using either an Olympus XI74 microscope (Center
Valley, PA) for epifluorescence, a Zeiss Axioplan
microscope equipped with an ApoTome and digital
AxioCamMR CCD camera, or a Zeiss LSM 150 con-
focal microscope (Thornwood, NY).
Differentiation of clonal MSCs
Passage two sorted cells were serially diluted in 96 well
plates to 0.3 cells per well. After 2 weeks in this media,
individual colonies were trypsinized, dispersed into
100 mm dishes, allowed to grow to confluence and plated
on fibronectin-coated slides. Myogenic differentiation
was induced by addition of 10 ng/mL transforming
growth factor (TGF)-b, 1 μg/mL insulin, 0.55 μg/mL
transferrin and 670 ng/mL selenium (Invitrogen, Carls-
bad, CA) for 6 days. These cells were immunostained for
a-actin (clone 1A4, Sigma-Aldrich) and myosin heavy
chain (clone hSM-V, Sigma-Aldrich). Adipogenic differ-
entiation was induced by culture in DMEM supplemen-
ted with 5% fetal bovine serum (FBS), 10 μM
dexamethasone, 50 μM indomethacin, 100 μM isobutyl-
methylxanthine (IBMX) and 10 μg/mL insulin for
21 days, as described [11] Formalin-fixed cells were
stained for neutral lipids with Oil Red O. Osteogenic dif-
ferentiation was accomplished by culture in DMEM sup-
plemented with 5% FBS, 100 nM dexamethasone, 10 mM
b-glycerophosphate and 50 μg/mL ascorbic acid for
21 days, as described [11]. Formalin-fixed cells were
stained for calcium phosphate with alizarin red.
To further assess differentiation state, cells were
solubilized and RNA extracted using a guanidine iso-
thiocyanate-phenol protocol (Trizol, InVitrogen).
Quantitative two-step real time PCR for differentiation
marker transcripts was performed using an Eppendorf
realplex2 (Westbury, NY). Transcripts were examined
for myocardin (MYOCD, forward sequence, CCCATG-
GACTCTGCCTATGC; reverse sequence, CTGAG-
GATCTGTAGCTGCAGGAAT), smooth muscle





peroxisome proliferator-activated receptor (PPAR)-g
(forward sequence, GGCCCACCAACTTCGGAATC;
reverse sequence, GTAAAGGGCTTGATGTCAAAG-
GAA), fatty acid binding protein 4/adipocyte protein-2
(FABP4, forward sequence, GGCTTTGCCACAAG-
GAAAGTG; reverse sequence, CGCCCAGTTTGAAG-
GAAATCTC), osteopontin/secreted phosphoprotein
1 (SSP1, forward sequence, CTCACCATTCGGATGA
GTCTGAT; reverse sequence, AGGGACGATTG-
GAGTGAAAGTG) and osteocalcin/bone g-carboxyglu-
tamate (gla) protein (BGLAP, forward sequence,
CAGCTTGGCCCAGACCTA; reverse sequence,
GCCAGGGTCAGCAGAGTG), Expression levels were
normalized to that of glyceraldehyde 3-phosphate
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dehydrogenase (GAPDH; forward sequence, TCCACT-
CACGGCAAATTCAAC); reverse sequence, CGCTC
CTGGAAGATGGTGATG).
Western analyses
Mouse lung MSCs were washed in PBS, homogenized in
50 mM Tris (pH 7.5), 100 mM NaCl, 50 mM NaF,
40 mM b-glycerophosphate, 2 mM EDTA, 200 μM
Na3VO4, and 1% Triton X-100 containing complete pro-
tease inhibitors (Roche Diagnostics, Indianapolis, IN).
After centrifugation at 10,000 g for 30 min to remove
nuclei and cell particles, supernatants were resolved by
SDS-PAGE and transferred to nitrocellulose. Mem-
branes were probed with mouse monoclonal anti-
a-smooth muscle actin (MAb 1A4; Calbiochem, San
Diego, CA), mouse monoclonal anti-myosin heavy chain
(MHC) (MAb HSM-V; Sigma-Aldrich, St. Louis, MO)
or mouse monoclonal anti-b-actin (Sigma). Antibody
binding was detected in Westerns with a peroxidase-
conjugated anti-rabbit or anti-mouse IgG and chemilu-
minescence (Thermo-Pierce, Rockford, IL).
Gene arrays
We examined the gene expression profile of MSCs using
the Illumina MouseWG-6 expression BeadChip platform
(San Diego, CA). This system detects 26,766 coding
transcripts with well-established annotations, 6,277 cod-
ing transcripts with provisional annotations and 56 non-
coding transcripts with well-established annotations.
Total RNA was extracted using the RNeasy Plus Mini
kit (Qiagen, Valencia, CA). Further preparation and ana-
lysis was carried out by the University of Michigan
Sequencing Core, according to the chip manufacturer’s
recommended protocol. Hybridized biotinylated cRNA
was detected with streptavidin-Cy3 and quantitated
using an Illumina BeadArray Reader. The gene expres-
sion profile of lung MSCs was compared to primary
mouse lung fibroblasts as well as primary mouse bone
marrow MSCs, which were isolated from the femurs of
OVA-treated mice by flow cytometry, using gates identi-
cal to those used for lung MSCs.
For microarray statistical analysis, background-cor-
rected values for each probe on the BeadChip array
were extracted using GenomeStudio Data Analysis Soft-
ware (Illumina). Detection p-values were computed
using a non-parametric method. Probe signals are
ranked relative to signals of negative controls. Detection
p-value = 1-R/N, where R is the rank of the gene signal
relative to negative controls and N is number of nega-
tive controls. Statistical differences in gene expression
between lung and bone marrow-derived cells were cal-
culated using the Illumina Custom differential expres-
sion algorithm. Multiple tests were corrected by the
Benjamini and Hochberg false discovery rate [29]. For
qPCR, data were normalized for GAPDH, and differ-
ences in gene expression analyzed by paired t test.
Isolation and characterization of MSCs from the BAL of a
patient with asthma
This study was approved by the University of Michigan
Institutional Review Board. After informed consent,
BAL fluid was obtained from three pediatric asthma
patients who were undergoing diagnostic flexible
bronchoscopy. Cells were sedimented for 5 min at 500
× g, washed in media, counted, and serial dilutions of
100,000 to 100 cells were plated and allowed to grow
for 21 days CellCe, Single colonies were isolated,
expanded, and assessed for cell surface markers and
pluripotency. Cell surface markers and differentiation
potential were compared to human neonatal lung MSCs
[11] and primary human lung fibroblasts (Lonza, Walk-
ersville, MD). Cell surface markers were examined by
flow cytometry using human-specific antibodies (BioLe-
gend). Cells were differentiated along adipogenic and
osteogenic lines as described above. For chondrogenic
differentiation, cells were differentiated along cartilage
lines by first sedimenting (10 min at 500 × g) 200,000
trypsinized cells in a sterile 15 mL polypropylene culture
tube and maintaining them as a pellet for 21 days in
serum-free DMEM composed with 10 ng TGF-b1 and
10 ng bone morphogenetic protein-4/mL [30]. At the
end of this time cell pellets were fixed overnight in for-
malin, processed for paraffin embedding and sectioning,
and stained for chondroitin sulfate with Alcian blue[31].
A nuclear fast red counterstain was used to help distin-
guish nuclei acids from acid mucopolysaccharides.
Results
OVA sensitization and challenge is associated with the
appearance of Stro-1, CD73, and CD105-positive cells
with high colony forming potential
We used flow cytometry to examine cells for cell surface
markers typically associated with MSCs (Figure 2). Cells
from whole lung digests were plated on plastic for five
days to enrich for adherent lung fibroblast cells. We
stained live cells from PBS- and OVA-treated mice for
Stro-1, CD73, CD105, CD34 and CD45. We found a
subpopulation of fibroblast-like cells from OVA-treated
mice which showed greater Stro-1 expression (Figure
2A). We found distinct side populations of cells from
OVA-treated mice which showed greater CD105 expres-
sion (Figures 2B and 2C), Both populations gated in the
same forward scattering area. To eliminate hematopoie-
tic cells, CD34 and CD45-positive cells were delineated
by the windows shown (Figures 2B and 2C) and further
gated for CD73 and CD105 expression, leaving a popu-
lation of Stro-1-, CD73- and CD105-positive cells (Fig-
ure 2D). This population represents about 0.04% of the
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Figure 2 OVA treatment increases the fraction of mesencymal stromal cell antigen-positive lung cells. Collagenase dispersible cells were
prepared from the lungs of PBS- (left column) or OVA-treated mice (right column). Single cell suspensions from PBS or OVA-treated mouse
lungs were allowed to adhere to polystyrene plates for 5 days, trypsinized, blocked with 1% BSA and incubated with AF350-conjugated anti-Stro-
1, AF488 anti-CD34, AF750 anti-CD45, AF555 anti-CD105, and AF633 anti-CD73. Data from 100,000 events are shown, with Stro-1 fluorescence
intensity in blue, CD73 in red and CD105 in green. Gates were drawn to select a Stro-1-positive (A), low CD34 (B) and low CD45 population (C).
In panel D, the gates indicated in panels A, B and C were used to produce the CD73 vs. CD105 plots shown (dot size is adjusted to make the
lower cell numbers visible). The average number of cells in the various CD73-, CD105-positive subpopulations shown is provided Table 1. There
was a significant increase in the number of CD34-, CD45-negative, CD73-, CD105-positive cells in lungs from OVA-treated mice.
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original lung cell digest (Table 1) and is here designated
a lung MSC population. These cells were rarely detect-
able in PBS-treated lungs (0.004%).
The potential of adherent cells to form colonies was
assessed by colony-forming unit-fibroblast (CFU-F)
assay [28]. Sorted cells and primary mouse lung fibro-
blasts were serially diluted and 100 cells were plated in
DMEM with 10% FBS. After 14 days, plates were fixed
and stained. Sorted cells demonstrated a CFU-F of 29.0
± 1.4 (mean ± SEM, n = 4) out of 100 cells plated, sig-
nificantly greater than unsorted lung cells from either
PBS (1.5 ± 0.1)- or OVA-treated (8.9 ± 2.2) mice (n = 6
for both groups, P < 0.05, ANOVA).
Sorted and clonal cells were trypsinized after two
further passages and processed for flow cytometry using
the same antibodies with which they were initially
sorted. The sorted cells retained MSC cell surface anti-
gens after propagation, and also stained positively for
CD90.2 and Sca-1 (Figure 3). In the mouse lung, the
CD45-, CD31-negative, Sca-1-positive phenotype has
been associated with the mesenchymal progenitor cell
lineage [32]
We examined sections from PBS- and OVA-treated
mouse lungs for surface markers typically associated
with MSCs including Stro-1, CD73 and CD105. In
humans, Stro-1 is almost exclusively found on bone
marrow-derived stromal cells [33]. Stro-1 localization
has also been noted in mouse mesenchymal cells of the
bone marrow [34] and developing periodontium [35].
CD73 (SH3/SH4) and CD105 (SH2/endoglin) are loca-
lized at the plasma membrane of bone marrow
mesenchymal stem cells [36]. A small number of peri-
bronchial cells stained positively for Stro-1, CD73,
CD105 and a-smooth muscle actin (Figure 4).
Sorted Stro-1(+), CD73(+), CD105(+) cells may be
differentiated along a variety of mesenchymal lineages
Cells from Stro-1-, CD73-, CD105-positive, CD34-,
CD45-negative subpopulations were seeded onto plastic
dishes. Only the high CD73, high CD105 cells grew well
and were studied further. To isolate individual clones,
passage two sorted cells were serially diluted in 96 well
plates to 0.3 cells per well. After two weeks of growth in
this media, wells with cells were trypsinized. Cells were
dispersed into 100 mm dishes, allowed to grow to
confluence, plated on fibronectin-coated slides and dif-
ferentiated along adipogenic, osteogenic and myofibro-
blast lines (Figures 5, 6). When cells are treated with
adipogenic medium (10 μM dexamethasone, 100 μM
IBMX, 50 μM indomethacin and 100 μg/mL insulin),
cells accumulated neutral lipid vesicles (Figure 5A) and
expressed more mRNA encoding PPARG and FABP4
(Figure 5B). Osteogenic differentiation with 0.1 μM dex-
amethasone, 10 mM b-glycerophosphate and 50 μg/ml
ascorbic acid caused cells to increase calcium phosphate
deposition as well as mRNA expression of SSP1 and
BGLAP. TGF-b treatment induced expression of
MYOCD, MHC11, and TAGLN (Figure 6A). Western
analyses of these cells demonstrated significantly more
a-actin and MHC (Figure 6B). The size of a-actin-posi-
tive cells was increased, as assessed by increased forward
scatter (Figure 6C). When cells were treated with TGF-
b, many differentiated into filamentous a-actin- and
MHC-expressing myofibroblasts (Figure 6D). On the
basis of their cell surface markers, ability form colonies,
and differentiation potential, these cells meet established
criteria for MSCs [37].
Sorted lung MSCs have a significantly different gene
expression pattern from either unsorted lung fibroblasts
To better characterize the differences between sorted
lung MSCs and other resident fibroblast-like cells,
mRNA samples from three different sorted clonal lines
were used to analyse patterns of gene expression. Out of
33043 mouse mRNA transcripts, a detection p ≤ 0.05
for 12,331 genes of mouse lung MSCs was obtained.
Global transcript expression concordance (r2) between
the sorted lung MSCs and adherent unsorted lung fibro-
blasts was 0.7539 (Figure 7A). We found a differential p
value of ≤0.05 for 5559 genes between sorted mouse
lung MSCs and unsorted adherent lung fibroblasts. On
the other hand, there was high concordance between
lung and bone marrow MSCs (r2 = 0.9872) (Figure 7B).
Thus, the sorted multipotent stromal cells represent a
distinct subpopulation of cells within the lung.
Of the 5559 genes differing between lung MSCs and
lung fibroblasts, 2480 were upregulated. These genes
included selected cytokines and paracrine factors; recep-
tors, signaling intermediates and transcriptional regula-
tors of the TGF-b1 and TNF-a pathways; and receptor
Table 1 Populations of Stro-1-, CD105-positive, CD34-CD45-negative cells from PBS- and OVA-treated lungs
Population of Cells Analysed PBS OVA
Total population 100,000 100,000
High Stro-1, low CD34, low CD45, low CD73, high CD105 14 ± 7 36 ± 19
High Stro-1, low CD34, low CD45, medium CD73, high CD105 12 ± 6 138 ± 61
High Stro-1, low CD34, low CD45, high CD73, high CD105 4 ± 1 41 ± 13*
Cells obtained and sorted as described above were counted from 3 sets of 5 PBS- or OVA-treated mice (*P < 0.05, unpaired t-test).
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Figure 3 Sorted cells retain cell surface markers typically associated with multipotent stromal cells. The CD34-, CD45-negative, Stro-1-,
CD73-, CD105-positive cell fraction was plated, grown to confluence, passaged three times, removed with cell dissociation buffer, and bound to
either AF488-conjugated control Ig (open curve) or antibody to the indicated antigen (grey curve). Cells in G0/G1 phase were gated by staining
with propidium iodide. Event number is indicated on the y-axis.
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Figure 4 Presence of Stro-1-, CD73-, CD105-positive cells in the lungs of OVA-treated mice. A-D. Sections from OVA-sensitized and
-challenged mouse lungs (at 630× original magnification) were stained for nuclei with Hoescht 33258. These are shown as a negative grayscale
image in black. AF633-conjugated anti Stro-1 is shown in blue (A), AF555-conjugated anti-CD73 is shown in red (B) and AF488-conjugated anti-
CD105 is shown in green (C). In D, the merged image shows co-localization of CD73 and CD105 (yellow/orange) and Stro-1, CD73 and CD105
(white). The insets show isolated cells at higher magnification. (There is some non-specific crossreactivity with the epithelial basement membrane
in the red channel.) E-H. Lung sections from OVA-treated mice were stained for nuclei with Hoechst 33258 (black), AF633-conjugated anti-Stro-1
(blue, E), AF555-conjugated anti-CD73 (red, F) and AF488-conjugated anti-a-smooth muscle actin (green, G). In H, the merged image shows co-
localization of Stro-1 and CD73 (magenta), Stro-1 and a-actin (turquoise) and Stro-1, CD73 and a-actin (white). The insets show isolated cells at
higher magnification. Some positive cells lie adjacent to the airway smooth muscle layer.
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Figure 5 Sorted Stro-1(+), CD73(+), CD105(+) cells may be differentiated along adipogenic and osteogenic lines. In panel A, cells were
differentiated for 21 days as described in the text. Adipogenic differentiation was monitored by staining for neutral lipids with Oil Red-O (stains
red). Osteogenic differentiation was assessed by staining of calcium phosphate with alizarin red (red). B. Four different single cell clones isolated
from different sorting experiments were exposed to adipogenic and osteogenic media (see text). Bars depict the fold increase in gene
expression by quantitative PCR (mean ± SEM, *p < 0.05, paired t test).
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tyrosine kinases and their downstream signaling inter-
mediates (Table 2 and Additional File 1, Table S1,
supplement).
Isolation of mesenchymal progenitor cells with surface
markers of MSCs from a patient with asthma
We have isolated pluripotent mesenchymal cells from
the tracheal aspirates of premature infants undergoing
mechanical ventilation for respiratory distress [11]. Acti-
vated fibroblasts have previously been isolated from
human asthma patients [24]. We examined the BAL
fluid of three children with asthma who were under-
going diagnostic flexible bronchoscopy. After two weeks
of culture, one sample yielded colonies of adherent cells.
These cells stained low for CD31, CD34 or CD45 and
high for Stro-1, CD73, CD105, and CD166 (Figure 8A).
Unlike normal human lung fibroblasts, but similar to
pluripotent mesenchymal cells from human neonates
[11], these cells could be differentiated along adipogenic,
osteogenic and chondrogenic lines (Figure 8B).
Figure 6 TGF-b induces myofibroblastic differentiation of lung MSCs. In panel A, three different clonal cell lines were incubated for 6 days
under serum-free conditions without or with 10 ng TGF-b/mL. A. qPCR reactions were run on the cDNA produced from RNA from the cells
assessing the relative expression of myosin heavy chain 11 (MHC11), transgelin (TAGLN), or myocardin (MYOCD). Expression of all three was
significantly elevated with TGF-b treatment (N = 3, p < 0.05). B. Western analyses demonstrated increases in a-actin and myosin heavy chain
(MHC) synthesis. Signals were quantified by densitometry and normalized to b-actin (N = 3, p < 0.05). C. TGF-b increases cell size and a-smooth
muscle actin expression. Forward scatter (top panel) and a-actin immunostaining (bottom panel) for cells serum deprived for 6 days (green) or
treated with TGF-b (10 ng/ml) for 6 days (orange). D. TGF-b produces an increase in cell size, a-actin, and MHC immunostaining. Myofibroblastic
differentiation was assessed by staining with AF488-conjugated anti-MHC (green) and anti a-actin-Cy3 conjugate (red). Co localization of a-actin
and MHC Is shown In yellow to orange. White bars indicate 100 μm.
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Together, these data suggest that pluripotent mesenchy-
mal cells may be identified in the BAL of human asthma
patients.
Discussion
Mesenchymal stem cells are multipotent cells capable of
differentiation into a select range of mesenchymal cell
types influenced by their microenvironment. They are
identified by their cell surface markers, high prolifera-
tion rate, ability to form colonies and differentiation
potential [37]. More recent work shows that mesenchy-
mal stem cells are not after all uniform, and that pluri-
potent mesenchymal cells may be separated into a
hierarchy with differential self-renewal potential and
multipotency [16].
Using cell sorting, we isolated a population of CD34-
and CD45-negative, Stro-1-positive, high CD73- and
CD105-positive cells. In humans, Stro-1 is almost exclu-
sively found on bone marrow-derived MSCs [33]. Stro-1
has been described in bone marrow-derived stem cells
in the mouse [34]. CD73 (SH3/SH4) and CD105 (SH2/
endoglin) are localized at the plasma membrane of bone
marrow mesenchymal stromal cells [36]. The CD34-
and CD45-negative, Stro-1-positive, high CD73- and
CD105-positive cells grew on plastic, demonstrated
ample colony-forming potential, and were capable of
differentiation to osteogenic, adipogenic, and myogenic
phenotypes. Taken together, these data suggest that
OVA-sensitization and -challenge increases the popula-
tion of MSCs in the lung.
While we did not determine the precise function of
MSCs in allergic airways disease, we consider two possi-
bilities to be most likely. First, MSCs could constitute a
source of airway myofibroblasts, leading to increased air-
way smooth muscle mass. Patients with severe asthma
also demonstrate an accumulation of myofibroblasts in
the airway subepithelium [19-21]. These alterations may
extend beyond the central airways to the distal airways
and lung parenchyma [23]. After allergen challenge,
myofibroblasts in the subepithelium of the asthmatic
airway may migrate to the smooth muscle layer [22].
Previous studies have noted increased airway smooth
muscle cell number in fatal and non-fatal asthma
[17,18], as well as OVA-sensitized and -challenged mice
[38]. Mesenchymal stem cells generally express low
levels of a-smooth muscle actin, but may express high
levels of this contractile protein upon TGF-b treatment
[11]. In multipotent stem cells from tracheal aspirates of
premature infants, autocrine production of TGF-b
further drives myofibroblastic differentiation,[13].
Finally, sorted lung MSCs were enriched for many tran-
scripts which could play a role in myofibroblast differen-
tiation and fibrosis including those encoding CD105/
endoglin, part of the TGF-b receptor complex; the TGF-
b family protein Gdf11 [39,40]; the TGF-b antagonists
Gremlin, Lefty1 and BMP-binding endothelial regulator
[41,42]; SMADs 2 and 3; NFATc3, a transcription factor
involved in TGF-b1 signaling in airway smooth muscle
[43]; and osteopontin which has been shown to be
required for TGF-b expression and lung fibrosis in bleo-
mycin- [44] and OVA-treated mice [45].
Another possible function of resident multipotent
stromal cells is immunomodulation. Lung-resident
mesenchymal stem cells from human lung allografts
inhibit T cell proliferation in vitro [46]. Intravenously-
administered murine mesenchymal stem cells derived
from plastic-adherent bone marrow cells protect
against bleomycin lung injury through the expression
of interleukin-1 receptor antagonist [47-49]. In addi-
tion, intratracheal pluripotent mesenchymal stem cells
have been shown to decrease endotoxin-induced lung
injury [50]. In the present study, sorted lung MSCs
were enriched in transcripts encoding the pro-inflam-
matory IL-6 family member cardiotrophin. This
Figure 7 Concordance of gene probe detection p-values
between sorted lung multipotent stromal cells, lung
fibroblasts (A) and bone marrow sorted cells (B). Parallel lines
signify 1.5 fold change based on average probe signal. There was
not a high degree of concordance between lung MSCs and lung
fibroblasts, suggesting that lung multipotent stromal cells represent
a unique population of cells in the lung.
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cytokine also is involved in ASM hypertrophy [43]. In
addition, cultured lung multipotent stromal cells also
produced MCP-1/CCL2 and KC/CXCL1, cytokines
that would be expected to increase airway inflamma-
tion. Several members of the prolactin 2c gene family
were greatly enriched in lung multipotent stromal
cells. While humans possess only one prolactin gene
used for both endocrine and paracrine functions, the
prolactins are a multigene family in mice [51,52]. The
prolactin-like peptides, also referred to as proliferins,
have been implicated in wound-healing [53], angiogen-
esis [54] and B cell tolerance [55].
We successfully isolated MSCs from a patient with
asthma, proof of concept that MSCs may be isolated
from the BAL of these patients. As noted above, multi-
potent mesenchymal stem cells have been isolated from
the tracheal aspirates of premature infants undergoing
mechanical ventilation for respiratory distress [11] and
Table 2 Selected genes upregulated in sorted lung MSCs relative to lung fibroblasts
Symbol average Lung MSCs average Lung fibroblast Fold difference Differential p-value
Secreted cytokines and paracrine factors
Prl2c3 20800 2.91 7147.77 1.00E-13
Prl2c4 16700 2.49 6706.83 1.01E-13
Prl2c2 16400 2.37 6919.83 1.01E-13
Efnb2 250 42.4 5.90 2.98E-08
Prl2c5 224 71.5 3.13 7.15E-08
Grem1 17700 2520 7.02 1.42E-06
Ptges3 2080 763 2.73 1.20E-05
Fgf10 3710 853 4.35 0.000233
Ctf1 265 109 2.43 0.000226
Ccl25 171 58.9 2.90 0.000239
Fgf7 7600 3580 2.12 0.00038
Efna4 176 85.3 2.06 0.00268
Bmper 2060 1020 2.02 0.0041
Lefty1 411 244 1.68 0.0163
Gdf11 52.3 7.81 6.70 0.0279
Thbs1 961 300 3.20 0.0293
Cx3cl1 384 81.6 4.71 0.0311
Sema3a 638 14.8 43.11 0.0367
Spp1 12500 8920 1.40 0.0469
TGF-b1 signaling
Smad2 334 86.4 3.87 5.67E-07
Smad3 889 410 2.17 5.67E-07
Mapk13 387 104 3.72 1.28E-06
Hdac2 2440 1300 1.88 1.58E-05
Trrap 207 54.2 3.82 4.02E-05
Hdac4 179 69.6 2.57 0.000433
Mapk11 115 30.3 3.80 0.000661
Tgfbrap1 603 195 3.09 0.00172
Nfatc3 287 121 2.37 0.00226
Hdac3 1080 377 2.86 0.00241
Hdac10 60.3 19.4 3.11 0.00378
Acvr2b 177 107 1.65 0.0308
Endogl1 77.5 39.1 1.98 0.0462
Abbreviations are: Prl2c3, encoding prolactin family 2, subfamily c, member 3; Prl2c4, prolactin family 2, subfamily c, member 4 ; Prl2c2. prolactin family 2,
subfamily c, member 2; Efnb2, ephrin B2; Prl2c5, prolactin family 2, subfamily c, member 5; Grem1, gremlin 1; Ptges3, prostaglandin E synthase 3; Fgf10, fibroblast
growth factor 10; Ctf1, cardiotrophin 1; Ccl25, chemokine (C-C motif) ligand 25; Fgf7, fibroblast growth factor 7 or keratinocyte growth factor; Efna4, ephrin A4;
Bmper, BMP-binding endothelial regulator; Lefty1, left right determination factor 1; Gdf11, growth differentiation factor 11 (BMP 11); Thbs1, thrombospondin 1;
Cx3cl1, chemokine (C-X3-C motif) ligand 1; Sema3a, sema domain, secreted, (semaphorin) 3A; Spp1, secreted phosphoprotein 1, osteopontin; Smad2, MAD
homolog 2 (Drosophila); Smad3, MAD homolog 3 (Drosophila); Mapk13, mitogen activated protein kinase 13 (p38); Hdac2, histone deacetylase 2; Trrap,
transformation/transcription domain-associated protein; Hdac4, histone deacetylase 4; Mapk11, mitogen-activated protein kinase 11 (p38 δ); Tgfbrap1,
transforming growth factor, beta receptor associated protein 1; Nfatc3, nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3; Hdac3, histone
deacetylase 3; Hdac10, histone deacetylase 10; Acvr2b, activin receptor IIB; Endogl1, endoglin (CD105);
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Figure 8 Isolation of a mesenchymal progenitor cells from the BAL of a patient with asthma. A. Cells are negative for CD31, CD34 and
CD45, and positive for Stro-1, CD73, CD105 and CD166. Mesenchymal cells from a patient with asthma (green) are compared with neonatal
lung mesenchymal cells (red). IgG control is shown in black. B. Colonies of cells derived from the tracheal aspirates of human premature infants
and a patient with asthma were isolated, grown and treated for differentiation along fat, bone or cartilage lines. Responses were compared with
primary human lung fibroblasts. Shown are oil red o staining for fat droplets (left column of panels), alizarin red staining for calcium phosphate
(middle column of panels) or alcian blue staining for acid mucopolysaccharide sulfates (nuclear fast red counterstain).
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the bronchoalveolar lavage of patients who have under-
gone lung transplantation [12]. In the latter studies, cells
were grown from colonies identified 7-21 days after
initial plating on plastic [11,12]. In the present study,
MSCs were identified by flow cytometry after only 5
days of adherence to plastic, and by fluorescence micro-
scopy at the time of allergen challenge. Together, these
data provide stronger evidence that multipotent
mesenchymal cells are present in the lung in vivo. How-
ever, at this time it is premature to say whether MSCs
play a pathogenic role in human asthma.
In summary, we have found that allergen-sensitization
and -challenge leads to the emergence of a lung cell
population with the surface markers, differentiation
potential and clonogenic potential of multipotent stro-
mal cells. Further animal studies will be required to
determine the physiologic role of these cells. Finally,
additional work is needed to determine whether lung
MSCs play a role in human asthma.
Additional material
Additional file 1: Additional selected genes upregulated in sorted
lung MSCs relative to lung fibroblasts. This file contains a Table, Table
S1, listing additional genes upregulated in sorted lung MSCs relative to
total lung fibroblasts
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